Weiter zum Inhalt
Toggle navigation
English
English
Favoritenliste (
0
)
(Voll)
Kontakt
Mein Konto
Abmeldung
Mein Konto
Suche
Filter bei nächster Suche beibehalten
#:"(allfields_unstemmed:2019-nCov OR allfields:2019nCov OR allfields_unstemmed:2019nCov OR allfields_unstemmed:Sars-CoV-2 OR allfields_unstemmed:COVID-19 OR allfields_unstemmed:Sars-CoV-2 OR allfields_unstemmed:COVID-19 NOT format:Book NOT collection_details:ZDB-2-SEB)"
topic_facet:"Medical Condition: COVID-19;Therapeutic area: Diseases [C] - Virus Diseases [C02]"
(allfields_unstemmed:2019-nCov OR allfields:2019nCov OR allfields_unstemmed:2019nCov OR allfields_unstemmed:Sars-CoV-2 OR allfields_unstemmed:COVID-19 OR allfields_unstemmed:Sars-CoV-2 OR allfields_unstemmed:COVID-19 NOT format:Book NOT collection_details:ZDB-2-SEB)
Erweiterte Suche
Suchverlauf
Struktursuche
Narrative Service
Drug Overviews
Info Guide
/vufind/Search/Results?filter%5B%5D=%23%3A%22%28allfields_unstemmed%3A2019-nCov+OR+allfields%3A2019nCov+OR+allfields_unstemmed%3A2019nCov+OR+allfields_unstemmed%3ASars-CoV-2+OR+allfields_unstemmed%3ACOVID-19+OR+allfields_unstemmed%3ASars-CoV-2+OR+allfields_unstemmed%3ACOVID-19++NOT+format%3ABook+NOT+collection_details%3AZDB-2-SEB%29%22&filter%5B%5D=topic_facet%3A%22Medical+Condition%3A+COVID-19%3BTherapeutic+area%3A+Diseases+%5BC%5D+-+Virus+Diseases+%5BC02%5D%22&lookfor=%22Recruitment+Status%3A+Authorised-recruitment+may+be+ongoing+or+finished%22&type=Subject
/vufind/Search/Results?filter%5B%5D=%23%3A%22%28allfields_unstemmed%3A2019-nCov+OR+allfields%3A2019nCov+OR+allfields_unstemmed%3A2019nCov+OR+allfields_unstemmed%3ASars-CoV-2+OR+allfields_unstemmed%3ACOVID-19+OR+allfields_unstemmed%3ASars-CoV-2+OR+allfields_unstemmed%3ACOVID-19++NOT+format%3ABook+NOT+collection_details%3AZDB-2-SEB%29%22&filter%5B%5D=topic_facet%3A%22Medical+Condition%3A+COVID-19%3BTherapeutic+area%3A+Diseases+%5BC%5D+-+Virus+Diseases+%5BC02%5D%22&lookfor=%22Recruitment+Status%3A+Authorised-recruitment+may+be+ongoing+or+finished%22&type=Subject
Search /vufind/Search2/Results?filter%5B%5D=%23%3A%22%28allfields_unstemmed%3A2019-nCov+OR+allfields%3A2019nCov+OR+allfields_unstemmed%3A2019nCov+OR+allfields_unstemmed%3ASars-CoV-2+OR+allfields_unstemmed%3ACOVID-19+OR+allfields_unstemmed%3ASars-CoV-2+OR+allfields_unstemmed%3ACOVID-19++NOT+format%3ABook+NOT+collection_details%3AZDB-2-SEB%29%22&filter%5B%5D=topic_facet%3A%22Medical+Condition%3A+COVID-19%3BTherapeutic+area%3A+Diseases+%5BC%5D+-+Virus+Diseases+%5BC02%5D%22&lookfor=%22Recruitment+Status%3A+Authorised-recruitment+may+be+ongoing+or+finished%22&type=Subject
PubPharm (38)
1
An international randomised trial of additional treatments for COVID-19 inhospitalised patients who are all receiving the local standard of care : An international randomised trial of additional treatments for COVID-19 inhospitalised patients who are all receiving the local standard of care - Solidarity
enthalten in:
WHO International Clinical Trials Registry Platform
| 2022
Wird geladen...
2
An international randomised trial of additional treatments for COVID-19 inhospitalised patients who are all receiving the local standard of care : An international randomised trial of additional treatments for COVID-19 inhospitalised patients who are all receiving the local standard of care - Solidarity
enthalten in:
WHO International Clinical Trials Registry Platform
| 2022
Wird geladen...
3
Reparixin 1200 mg three times a day as add-on therapy to standard of care to limit disease progression in hospitalised adult patients with COVID-19 : Reparixin 1200 mg three times a day as add-on therapy to standard of care to limit disease progression in hospitalised adult patients with COVID-19. A multinational, multicentre, randomised, double blinded, placebo-controlled, parallel-group phase III trial. - REP0321 Fase 3
enthalten in:
WHO International Clinical Trials Registry Platform
| 2022
Wird geladen...
4
Reparixin 1200 mg three times a day as add-on therapy to standard of care to limit disease progression in hospitalised adult patients with COVID-19 : Reparixin 1200 mg three times a day as add-on therapy to standard of care to limit disease progression in hospitalised adult patients with COVID-19. A multinational, multicentre, randomised, double blinded, placebo-controlled, parallel-group phase III trial. - REP0321 Fase 3
enthalten in:
WHO International Clinical Trials Registry Platform
| 2022
Wird geladen...
5
a cohort study for the evaluation of the use of neutralizing monoclonal SARS-CoV-2 antibodies : The Dutch neutralizing monoclonal antibody cohort against COVID-19:a cohort study for the evaluation of the use of neutralizing monoclonal SARS-CoV-2 antibodies - TURN-COVID
enthalten in:
WHO International Clinical Trials Registry Platform
| 2021
Wird geladen...
6
a cohort study for the evaluation of the use of neutralizing monoclonal SARS-CoV-2 antibodies : The Dutch neutralizing monoclonal antibody cohort against COVID-19:a cohort study for the evaluation of the use of neutralizing monoclonal SARS-CoV-2 antibodies - TURN-COVID
enthalten in:
WHO International Clinical Trials Registry Platform
| 2021
Wird geladen...
7
Immunogenicity and reactogenicity following a booster dose of COVID-19 mRNA vaccine (Pfizer-BioNtech) and two adjuvanted sub-unit vaccines (SP/GSK) administered in adults who received 2 doses of Pfizer-BioNTech mRNA vaccine as a primary vaccination: A randomized, single-blinded multicenter clinical trial : Immunogenicity and reactogenicity following a booster dose of COVID-19 mRNA vaccine (Pfizer-BioNtech) and two adjuvanted sub-unit vaccines (SP/GSK) administered in adults who received 2 doses of Pfizer-BioNTech mRNA vaccine as a primary vaccination: A randomized, single-blinded multicenter clinical trial - CoviBOOST
enthalten in:
WHO International Clinical Trials Registry Platform
| 2021
Wird geladen...
8
Immunogenicity and reactogenicity following a booster dose of COVID-19 mRNA vaccine (Pfizer-BioNtech) and two adjuvanted sub-unit vaccines (SP/GSK) administered in adults who received 2 doses of Pfizer-BioNTech mRNA vaccine as a primary vaccination: A randomized, single-blinded multicenter clinical trial : Immunogenicity and reactogenicity following a booster dose of COVID-19 mRNA vaccine (Pfizer-BioNtech) and two adjuvanted sub-unit vaccines (SP/GSK) administered in adults who received 2 doses of Pfizer-BioNTech mRNA vaccine as a primary vaccination: A randomized, single-blinded multicenter clinical trial - CoviBOOST
enthalten in:
WHO International Clinical Trials Registry Platform
| 2021
Wird geladen...
9
Clinical trial of anti-coagulant drug for COVID-19 inpatients : Australasian COVID-19 Trial (ASCOT) ADAptive Platform Trial - ASCOT ADAPT
enthalten in:
WHO International Clinical Trials Registry Platform
| 2021
Wird geladen...
10
Clinical trial of anti-coagulant drug for COVID-19 inpatients : Australasian COVID-19 Trial (ASCOT) ADAptive Platform Trial - ASCOT ADAPT
enthalten in:
WHO International Clinical Trials Registry Platform
| 2021
Wird geladen...
1
2
3
4
Nächster »
[4]
Filter & Sortierung
Treffer pro Seite
10
20
50
Sortieren
Relevanz
Neueste zuerst
Älteste zuerst
Verfasser
Zeitschriftentitel
Bibliothek
Standort (Printmedien)
Verwandte Substanzen
Verwandte Substanzen werden ermittelt...
Verwandte Erkrankungen/Symptome
Verwandte Erkrankungen/Symptome werden ermittelt...
Verwandte Gene
Verwandte Gene werden ermittelt...
Systematic Reviews
Clinical Studies
Patente
Filter aufheben
Covid-19/SARS-CoV-2
Exclude Systematic Reviews
Exclude Clinical Studies
Exclude Patents
Ihre gewählten Filter
Filter bei nächster Suche beibehalten
Filter aufheben
Thema: Medical Condition: COVID-19;Therapeutic area: Diseases [C] - Virus Diseases [C02]
Medienart
38
Aufsätze
38
E-Artikel
38
E-Ressourcen
Zeitschriftentitel
38
WHO International Clinical Trials Registry Plat...
Thema
38
610
Medical Condition: COVID-19;Therapeutic area: D...
38
Recruitment Status: Authorised-recruitment may ...
38
Study Type: Interventional
18
Phase: Phase 3
10
Phase: Phase 2
10
Phase: Phase 4
Alle anzeigen ...
weniger ...
Erscheinungszeitraum
4
2022
16
2021
18
2020
Erscheinungsjahr(e)
Von:
Bis:
Sprache
38
Englisch
Haven't found what you're looking for?
Wird geladen...